# Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

> **NCT01186991** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 185 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Onartuzumab
- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Bevacizumab Placebo
- **DRUG:** Onartuzumab Placebo

## Key facts

- **NCT ID:** NCT01186991
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2017-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01186991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01186991, "Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01186991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*